Clinical Trial Update: Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating preventative adoptive transfer of peptide-stimulated CMV/EBV-specific T-cells after allogeneic stem cell transplantation; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Stem Cell Transplant Recipients

Drugs mentioned

• CMV/EBV-specific T-cells (peptide-stimulated)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Patients Undergoing Allogeneic Stem Cell Transplantation | Phase 1, Phase 2 | Status: COMPLETED